Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells Qi ZhangXiao-Ting LiHong-Yu Han Original Article 29 March 2018 Pages: 969 - 977
Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells Qi ZhangXiao-Ting LiHong-Yu Han Correction 30 April 2018 Pages: 979 - 980
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis Sakura IizumiAtsuo TakashimaNarikazu Boku Original Article 29 March 2018 Pages: 981 - 989
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer James D. ByrneMohammad R. N. JajjaJen Jen Yeh Original Article 30 March 2018 Pages: 991 - 998
Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner Fei WuYun LinQingyong Liu Original Article 31 March 2018 Pages: 999 - 1006
Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer Yan-qin LanLing-jun KongDong-ta Zhong Original Article 04 April 2018 Pages: 1007 - 1015
A phase II study of modified FOLFIRINOX for chemotherapy-naĂŻve patients with metastatic pancreatic cancer Masato OzakaHiroshi IshiiJunji Furuse Original Article 09 April 2018 Pages: 1017 - 1023
Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice Aiping TianHaizhen LuYungchi Cheng Original Article 09 April 2018 Pages: 1025 - 1033
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study Chu MatsudaMichitaka HondaHideyuki Mishima Original Article 11 April 2018 Pages: 1035 - 1041
Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer Toshirou FukushimaYuuki WakatsukiTomonobu Koizumi Original Article 11 April 2018 Pages: 1043 - 1050
Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab Satoru NiheiJunya SatoNaoto Morikawa Original Article 12 April 2018 Pages: 1051 - 1059
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma Steven LacyJace NielsenMatt Hutmacher Original Article Open access 17 April 2018 Pages: 1061 - 1070
A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types Steven LacyBei YangMatt Hutmacher Original Article Open access 23 April 2018 Pages: 1071 - 1082
A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification Bo XuYuyou DengChunxi Wang Original Article 17 April 2018 Pages: 1083 - 1093
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein George E. DuranVolker DerdauBranimir I. Sikic Original Article 19 April 2018 Pages: 1095 - 1103
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases Kohei FujitaNaohiro UchidaTadashi Mio Original Article 19 April 2018 Pages: 1105 - 1109
IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1) Jing DuYuanqiao HeHongjun Ruan Original Article 24 April 2018 Pages: 1111 - 1119
Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease Hiroyoshi KoideMasayuki TsujimotoKohshi Nishiguchi Original Article 24 April 2018 Pages: 1121 - 1128
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies Boaz MendzelevskiGeorg FerberPhilip T. Sager Clinical Trial Report Open access 30 March 2018 Pages: 1129 - 1141